BullFrog AI Holdings Inc Unit (BFRG)

BullFrog AI Holdings Inc. is a healthcare technology company listed on NASDAQ under the ticker BFRG. The company focuses on applying artificial intelligence and machine learning to medical and biopharmaceutical data analysis in the United States. Its bfLEAP platform is designed to analyze preclinical and clinical datasets for biotechnology and pharmaceutical clients as well as other organizations. BullFrog AI also is advancing a pipeline that includes BF-222, a mebendazole-based formulation in Phase 1 for glioblastoma, BF-223, a preclinical mebendazole prodrug for glioblastoma, and BF-114, a discovery-stage candidate being studied for obesity and chronic liver diseases. In addition, the company has licensing agreements with George Washington University and Johns Hopkins University and a research partnership with the Lieber Institute for Brain Development focused on precision treatments for central nervous system disorders.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.